As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.
Among dozens of players that are racing to get their CAR-T therapies into the fast-growing Chinese oncology market, some may not get it right and that could cost the sector dearly.
Despite China having the highest number of registered CAR-T studies in the world, none are at the investigative new drug...